S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Own Dollar General? Hurry and take this advice before earnings
Recent Reports Are A Wake-Up Call For Investors (Ad)
Black Swan: this small cap surged over 1000% last week
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Economists predict US inflation will keep cooling and the economy can avoid a recession
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: US futures follow global markets lower ahead of raft of jobs data this week
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Own Dollar General? Hurry and take this advice before earnings
Recent Reports Are A Wake-Up Call For Investors (Ad)
Black Swan: this small cap surged over 1000% last week
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Economists predict US inflation will keep cooling and the economy can avoid a recession
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: US futures follow global markets lower ahead of raft of jobs data this week
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Own Dollar General? Hurry and take this advice before earnings
Recent Reports Are A Wake-Up Call For Investors (Ad)
Black Swan: this small cap surged over 1000% last week
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Economists predict US inflation will keep cooling and the economy can avoid a recession
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: US futures follow global markets lower ahead of raft of jobs data this week
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Own Dollar General? Hurry and take this advice before earnings
Recent Reports Are A Wake-Up Call For Investors (Ad)
Black Swan: this small cap surged over 1000% last week
Man kills 4 relatives in Queens knife rampage, injures 2 officers before he's fatally shot by police
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
AppLovin (APP): Losing its shareholders lovin'?
Economists predict US inflation will keep cooling and the economy can avoid a recession
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Stock market today: US futures follow global markets lower ahead of raft of jobs data this week
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

Genfit Stock Price, News & Analysis (OTCMKTS:GNFTF)

$3.80
-0.34 (-8.21%)
(As of 06/7/2023)
Compare
Today's Range
$3.68
$4.20
50-Day Range
$3.80
$3.80
52-Week Range
$3.13
$4.39
Volume
2,400 shs
Average Volume
1,225 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GNFTF stock logo

About Genfit Stock (OTCMKTS:GNFTF)

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GNFTF Stock Price History

GNFTF Stock News Headlines

Genfit Share Price (GNFT.PA)
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
Genfit reports 9M results
Kepler Capital Sticks to Their Buy Rating for Genfit (GNFTF)
SVB Securities Remains a Buy on Genfit SA (GNFT)
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
Genfit Gears Up For Primary Biliary Cholangitis Trial Data
Genfit (GNFTF) Receives a Buy from Kepler Capital
GENFIT Announces 2023 Financial Calendar
A Long Wait For Genfit May Be Worth It
Genfit S.A. (GNFT)
Analyzing Genfit's Short Interest
Hedge Funds Are Betting On Genfit SA (GNFT)
See More Headlines
Receive GNFTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNFTF
CIK
N/A
Fax
N/A
Employees
154
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Jean-Francois Mouney (Age 68)
    Co-Founder & Chairman of the Board
    Comp: $402.3k
  • Mr. M. Pascal Prigent (Age 55)
    Chief Executive Officer
    Comp: $609.71k
  • Prof. Bart Staels (Age 60)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 49)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 55)
    Chief Operating Officer
  • Dr. Meriam Kabbaj Ph.D. (Age 49)
    Chief Technology Officer
  • Dr. Dean W. Hum Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $775.82k
  • Mr. Jean-Christophe Marcoux (Age 45)
    Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG
  • Mr. Laurent Lannoo (Age 53)
    Corporate Secretary & Director of Legal Affairs
  • Ms. Stefanie Magner J.D. (Age 42)
    Chief Compliance Officer & Executive VP of International Legal Affairs














GNFTF Stock Analysis - Frequently Asked Questions

How have GNFTF shares performed in 2023?

Genfit's stock was trading at $3.6901 on January 1st, 2023. Since then, GNFTF shares have increased by 3.0% and is now trading at $3.80.
View the best growth stocks for 2023 here
.

Are investors shorting Genfit?

Genfit saw a increase in short interest in October. As of October 31st, there was short interest totaling 60,300 shares, an increase of 394.3% from the October 15th total of 12,200 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
View Genfit's Short Interest
.

How do I buy shares of Genfit?

Shares of GNFTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:GNFTF) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -